Neurofibromatosis type 1 (NF1) is a genetic condition that causes tumors to grow along nerves in the skin, brain, and other parts of the body. These tumors are usually noncancerous (benign), but they ...

GOMEKLI is the first FDA-approved treatment for adult and pediatric NF1-PN, showing effective tumor reduction and manageable safety. SpringWorks Therapeutics has announced the FDA approval of GOMEKLI ...

Selumetinib received FDA approval for adults with NF1 and symptomatic, inoperable plexiform neurofibromas, based on the phase 3 KOMET trial results. The KOMET trial showed a 20% objective response ...

Treatment for neurofibromatosis type 1 may involve surgery, radiation, chemotherapy, or other methods. In some cases, doctors may take a “wait and see” approach. Neurofibromatosis type 1 (NF1), ...

There is currently no cure or treatment for NF1 that can reverse or prevent most complications. Because of this, medical management of the condition focuses on the early detection of treatable ...

Neurofibromatosis type 1 (NF1) is a genetic condition that affects the skin, nervous system, and other parts of the body. The condition, formerly called Von Recklinghausen disease, causes changes in ...

Benign tumors can grow along nerves anywhere in the body, causing complications such as pain, mobility issues, and psychosocial issues. Neurofibromatosis 1-associated plexiform neurofibromas (NF1-PN) ...

Health experts underscore that early detection of Neurofibromatosis Type 1 (NF1) signs and symptoms is essential for proper patient management and timely specialist referrals. Subsequent monitoring is ...

Researchers at Cincinnati Children's have identified a potential new way to relieve chronic pain linked to neurofibromatosis ...